Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/10693
Title: | Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). |
Authors: | Готько, Євген Степанович Marc Peeters Kelly Smith Oliner Timothy Jay Price Andres Cervantes Alberto F. Sobrero Michel Ducreux Thierry Andre Emily Chan Florian Lordick Cornelis JA Punt Andrew Strickland Gregory Wilson |
Issue Date: | 20-May-2014 |
Publisher: | ASCO Annual Meeting Proceedings, Т32, 3568 |
Abstract: | Improvements continued to be observed in the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS in WT RAS group vs WT KRAS exon 2 group in this update. Pts with MT RAS mCRC are unlikely to benefit by the addition of pmab to FOLFIRI, similar to pts with MT KRAS exon 2 mCRC. BRAF mutations appear to be associated with reduced OS among pts without RAS mutations regardless of tx arm. These findings support RAS testing to determine potentially appropriate pts with mCRC for pmab tx. Clinical trial information: NCT00339183 |
Type: | Text |
Publication type: | Стаття |
URI: | https://dspace.uzhnu.edu.ua/jspui/handle/lib/10693 |
Appears in Collections: | Наукові публікації кафедри радіології та онкології |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Updated_analysis.PDF | 395.16 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.